Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
Erstveröffentlichung
2018
Wissenschaftlicher Artikel
Published in
Lancet Oncology ; 19 (2018), 9. - S. 1215-1228. - ISSN 1470-2045. - eISSN 1474-5488
Link to publication
https://dx.doi.org/10.1016/S1470-2045(18)30414-5Institutions
UKU. Klinik für Innere Medizin IIISubject headings
[Free subject headings]: minimal residual disease | in-vitro | ii trial | rituximab | ibrutinib | cyclophosphamide | fludarabine | cll | chemoimmunotherapy | progression[DDC subject group]: DDC 610 / Medicine & health